-
Publication Venue For
-
Corrigendum to: Mild cognitive impairment in middle-aged adults with coronary microvascular dysfunction..
43:1776.
2022
-
The year in cardiovascular medicine 2021: acute cardiovascular care and ischaemic heart disease..
43:800-806.
2022
-
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement..
43:280-299.
2022
-
Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial..
43:148-149.
2022
-
Cardiovascular magnetic resonance imaging in suspected cardiac tumour: a multicentre outcomes study..
43:71-80.
2021
-
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score..
42:1676-1684.
2021
-
Continuous anticoagulation with catheter ablation: answers and questions..
40:3022-3025.
2019
-
Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials..
38:3502-3510.
2017
-
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial..
38:2813-2822.
2017
-
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial..
38:804-810.
2017
-
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease..
37:1993-2001.
2016
-
Lessons learned and a look to the future: The chronic ischemic heart disease (CICD) pilot registry.
37:161-163.
2016
-
Current worldwide nuclear cardiology practices andradiationexposure: Results from the 65country IAEA nuclear cardiology protocols cross-sectional study (INCAPS).
36:1689-1696.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
36:288-296.
2015
-
Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS.
35:138-138.
2014
-
Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials.
34:787-787.
2013
-
Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF.
32:964-964.
2011
-
Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction.
32:166-166.
2011
-
The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the Duke databank for cardiovascular disease.
32:134-134.
2011
-
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial.
32:872-872.
2011
-
Early in-ospital worsening heart failure predicts adverse outcome in patients.
30:719-719.
2009
-
Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.
30:115-115.
2009
-
Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).
30:424-425.
2009
-
Impact of anemia in patients with pulmonary hypertension.
30:260-260.
2009
-
Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.
30:6-6.
2009
-
Improved pulmonary insufficiency with inhaled vasodilator assessed by cardiac magnetic resonance imaging.
30:811-811.
2009
-
Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.
30:164-164.
2009
-
Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.
30:276-276.
2009
-
Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.
30:445-446.
2009
-
Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.
30:876-876.
2009
-
Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.
30:899-900.
2009
-
Racial disparities in survival in patients with pulmonary hypertension.
30:513-513.
2009
-
Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.
30:424-424.
2009
-
Worsening renal function in acute heart failure: change in BP and effects of relaxin.
30:1020-1021.
2009
-
Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry.
29:513-513.
2008
-
An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote.
29:328-328.
2008
-
Cognitive function and anticoagulation control in patients with atrial fibrillation.
29:258-258.
2008
-
Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery.
29:284-285.
2008
-
Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry.
29:326-326.
2008
-
Impact of incidentally discovered patent foramen ovale and its repair on perioperative outcomes in 13,260 cardiothoracic surgery patients.
29:124-124.
2008
-
Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).
29:679-679.
2008
-
Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI.
29:137-138.
2008
-
Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI.
29:447-447.
2008
-
Prevalence and predictors of dyssynchrony as determined by gated SPECT perfusion imaging in patients with left ventricular dysfunction.
29:5-5.
2008
-
Surgical treatment of anomalous coronary arteries passing between the great vessels in older adults may not improve survival.
29:7-7.
2008
-
Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.
29:345-346.
2008
-
Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative..
29:1103-1109.
2008
-
Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study..
29:1127-1135.
2008
-
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy..
29:871-879.
2008
-
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb..
29:880-887.
2008
-
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study..
29:748-756.
2008
-
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go..
29:609-617.
2008
-
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment..
29:315-323.
2008
-
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI..
28:2850-2857.
2007
-
Cardiovascular disease on a global scale: defining the path forward for research and practice..
28:2678-2684.
2007
-
A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial.
28:59-59.
2007
-
Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy.
28:59-59.
2007
-
Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes.
28:259-260.
2007
-
Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.
28:516-516.
2007
-
Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events.
28:689-689.
2007
-
Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.
28:184-184.
2007
-
Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women..
28:2064-2069.
2007
-
Outcomes for stenting in single and multivessel coronary artery disease using established and novel paclitaxel eluting stent platforms: COSTAR II.
28:577-577.
2007
-
Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI.
28:660-660.
2007
-
Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI.
28:9-9.
2007
-
Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin.
28:218-218.
2007
-
The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.
28:187-187.
2007
-
Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.
28:384-385.
2007
-
Retinal vessel diameter and cardiovascular mortality: pooled data analysis from two older populations..
28:1984-1992.
2007
-
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes..
28:1598-1660.
2007
-
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction..
28:1709-1716.
2007
-
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes..
28:1193-1204.
2007
-
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study..
28:1109-1116.
2007
-
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry..
28:980-988.
2007
-
Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial..
28:685-691.
2007
-
Ruminating on OAT: is the case closed?.
28:531-532.
2007
-
The cost of implantable defibrillators: how the perception of reality depends on perspective.
28:386-387.
2007
-
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials..
28:425-432.
2007
-
The high cost of implantable defibrillators..
28:388-391.
2007
-
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction..
28:415-424.
2007
-
Diabetes mellitus and insulin therapy in infective endocarditis..
28:3-4.
2007
-
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial..
27:3027-3032.
2006
-
Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?.
27:2737-2739.
2006
-
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes..
27:2956-2961.
2006
-
Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study..
27:2516-2523.
2006
-
Glucose, insulin, and acute myocardial infarction: Reply [4].
27:2142-2143.
2006
-
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study..
27:1530-1538.
2006
-
International variation in invasive care of the elderly with acute coronary syndromes..
27:1558-1564.
2006
-
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study..
27:1289-1297.
2006
-
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
27:1447-1458.
2006
-
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial..
27:1198-1206.
2006
-
Persistent and reversible cardiac dysfunction among amateur marathon runners..
27:1079-1084.
2006
-
Aborted myocardial infarction: a new target for reperfusion therapy..
27:901-904.
2006
-
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes..
27:527-533.
2006
-
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction..
27:419-426.
2006
-
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts..
27:323-329.
2006
-
Predictors of mortality and morbidity in patients with chronic heart failure..
27:65-75.
2006
-
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention..
26:2396-2403.
2005
-
Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance: reply.
26:2602-2602.
2005
-
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes..
26:2106-2113.
2005
-
Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction..
26:1937-1938.
2005
-
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial..
26:1964-1970.
2005
-
A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy..
26:1726-1733.
2005
-
Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes.
26:431-431.
2005
-
Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies..
26:1461-1474.
2005
-
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial..
26:1506-1512.
2005
-
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry..
26:1063-1069.
2005
-
The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study..
26:1235-1241.
2005
-
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction..
26:667-674.
2005
-
The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort..
26:421-422.
2005
-
Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality..
26:288-297.
2005
-
Assessing risk in FRISC..
26:103-104.
2005
-
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials..
26:128-136.
2005
-
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry..
25:1911-1919.
2004
-
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
25:1920-1926.
2004
-
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial..
25:1688-1694.
2004
-
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS..
25:1494-1501.
2004
-
Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging..
25:1419-1427.
2004
-
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes..
25:313-321.
2004
-
International variation in the use of evidence-based medicines for acute coronary syndromes..
24:2133-2141.
2003
-
Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry..
24:1763-1770.
2003
-
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial..
24:1807-1814.
2003
-
Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?.
24:1613-1615.
2003
-
International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2..
24:1640-1650.
2003
-
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)..
24:1414-1424.
2003
-
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction..
24:1515-1522.
2003
-
The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2..
24:1024-1034.
2003
-
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study..
24:897-908.
2003
-
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?.
24:522-531.
2003
-
P2275 Plasma homocystein levels independently correlate with angiographic extension of coronary artery disease.
24:436-436.
2003
-
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes..
24:172-181.
2003
-
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making..
24:182-189.
2003
-
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes..
23:1538-1545.
2002
-
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion..
23:1449-1455.
2002
-
Determinants of matrix metalloproteinases plasma concentration and activity in premature coronary atherosclerosis.
23:135-135.
2002
-
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy..
23:1202-1212.
2002
-
Effect of simvastatin on endothelial damage markers and clinical outcomes in acute coronary syndromes.
23:419-419.
2002
-
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial..
23:1102-1111.
2002
-
Assessment of myocardial viability by cardiovascular magnetic resonance imaging..
23:602-619.
2002
-
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction..
23:550-557.
2002
-
Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: has the time come for 'drive-through' angiography?.
23:191-194.
2002
-
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA..
22:2253-2261.
2001
-
ESPRIT in context: pharmacology matters!.
22:1965-1967.
2001
-
Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial.
22:700-700.
2001
-
Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.
22:524-524.
2001
-
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study..
22:1601-1612.
2001
-
Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.
22:121-121.
2001
-
Genetic variation in human Stromelysin-1 and Gelatinase B genes and acute coronary syndromes in young males.
22:164-164.
2001
-
Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials.
22:385-385.
2001
-
Low heart rate variability (triangular index method) predicts mortality independent of beta-blocker usage, LVEF, and other factors: ALIVE trial early findings.
22:701-701.
2001
-
Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial.
22:664-+.
2001
-
The ALIVE study: heart rate variability prospectively identifies patients at high risk of death after myocardial infarction.
22:696-+.
2001
-
Aortic stiffness and calcification..
22:181.
2001
-
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial..
21:1967-1978.
2000
-
Lack of progress in cardiogenic shock: lessons from the GUSTO trials..
21:1928-1936.
2000
-
Reperfusion synergism: will it be both sustained and safe?.
21:1913-1916.
2000
-
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators..
21:1750-1758.
2000
-
Electron beam computed tomography: on its way into mainstream cardiology?.
21:1556-1557.
2000
-
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction..
21:1502-1513.
2000
-
Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.
21:223-223.
2000
-
Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.
21:213-213.
2000
-
The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.
21:145-145.
2000
-
Use of a near-patient, whole blood, multi-marker strategy (MMS) for evaluation of patients with chest pain: Results of the CHECKMATE study.
21:19-19.
2000
-
Troponins in pericarditis: implications for diagnosis and management of chest pains patients..
21:798-800.
2000
-
American College of Cardiology/ European Society of Cardiology international study of angiographic data compression phase I. The effects of lossy data compression on recognition of diagnostic features in digital coronary angiography..
21:668-678.
2000
-
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry..
20:1182-1190.
1999
-
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries..
20:128-135.
1999
-
Mechanism of protective effects of ACE inhibition on coronary artery disease..
19 Suppl J:J2-J6.
1998
-
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes..
19 Suppl D:D22-D30.
1998
-
Nebulized prostacyclin for pulmonary hypertension: a step in the right direction..
18:1364-1365.
1997
-
Predictors of outcome of reperfusion therapy..
18:728-735.
1997
-
Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis..
17:978-980.
1996
-
Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial..
17:689-698.
1996
-
Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction..
17:399-406.
1996
-
Erratum: Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial (European Heart Journal (1996) 17 (689-698)).
17:1451.
1996
-
An overview of the results of the EPIC trial..
16 Suppl L:43-49.
1995
-
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor..
16 Suppl L:50-55.
1995
-
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..
16:1024-1026.
1995
-
Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia..
15:1356-1361.
1994
-
Extracellular lipid deposition in atherosclerosis..
11 Suppl E:20-28.
1990
-
Emerging role of the tissue renin-angiotensin systems in congestive heart failure..
11 Suppl B:65-71.
1990
-
In vitro analysis of jets by Doppler colour flow imaging: the importance of time to maximum jet area..
11:361-367.
1990
-
Left ventricular outflow acceleration in dilated cardiomyopathy its relationship with intrinsic ventricular load dynamics.
11:427-427.
1990
-
New interventional technology for the management of multivessel coronary artery disease..
10 Suppl H:52-56.
1989
-
Heart rate and metabolic response to competitive squash in veteran players: identification of risk factors for sudden cardiac death..
10:1029-1035.
1989
-
Two-dimensional echocardiography in arrhythmogenic right ventricular dysplasia..
10 Suppl D:22-26.
1989
-
Vascular and renal prostaglandins as counter-regulatory systems in heart failure..
9 Suppl H:15-19.
1988
-
Spontaneously healing infective endocarditis: An unrecognized phenomenon?.
8:327-330.
1987
-
Guidelines for exercise therapy of the elderly after myocardial infarction..
5 Suppl E:121-123.
1984
-
The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups..
5 Suppl E:113-115.
1984
-
Cannabis use is associated with prevalent coronary artery disease
2021
-
Cardiac MRI risk factors predict atrial arrhythmia development in repaired tetralogy of Fallot patients
2021
-
Mild cognitive impairment in middle-aged adults with coronary microvascular dysfunction
2021
-
Small nucleolar RNA SNORD3A: a potential new biomarker and molecular player in heart failure
2021
-
Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach
2020
-
Combination of fondaparinux with radial access is associated with low rates of in-hospital MACE and major bleeding events in patients with acute coronary syndrome
2020
-
Geographical region differences in the Cabana trials
2020
-
Impact of treatment strategies for AF on the progression and regression of AF type in the CABANA trial
2020
-
Incidence and risk of short episodes of atrial fibrillation detected with 14 days of continuous electrocardiographic monitoring
2020
-
Pharmacokinetics of apixaban in patients with end stage renal disease on hemodialysis and atrial fibrillation: results from the RENAL-AF trial
2020
-
Safety and efficacy of antithrombotic therapy according to stroke and bleeding risk in patients with atrial fibrillation and acute coronary syndrome or PCI: insights from AUGUSTUS
2020
-
Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE
2019
-
Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy
2019
-
Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study
2019
-
Effect of hypertension and systolic blood pressure on cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial
2019
-
Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy
2019
-
Impact of AF type on the outcome of atrial fibrillation ablation: insights from the CABANA trial
2019
-
Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation
2019
-
Implant procedure and lead handling characteristics of a novel active fixation quadripolar lead: Results from the Attain Stability Quad clinical trial
2019
-
Lipoprotein subclasses associated with high-risk coronary atherosclerotic plaque: insights from the PROMISE clinical trial
2019
-
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
2019
-
Network characteristics of a hypertension referral system in western kenya
2019
-
Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study
2019
-
Outcomes of catheter ablation for atrial fibrillation based on sex: data from the cabana trial
2019
-
Patients explanations of self-care in chronic heart failure: a grounded theory analysis of qualitative data from PANACEA-HF Phase 1
2019
-
Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study
2019
-
Risk of stroke in hypertensive patients with atrial fibrillation treated with oral anticoagulants
2019
-
Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis
2019
-
Agent Orange exposure in veterans with heart failure
2018
-
Association of hepatic steatosis with adverse cardiovascular events: insights from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) trial
2018
-
Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial
2018
-
Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry
2018
-
Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial
2018
-
Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis
2018
-
Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial
2018
-
Can biomarkers be used to predict cardiopulmonary exercise test performance in patients with chronic heart failure?
2018
-
Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial
2018
-
Characterization of major and clinically relevant non-major bleeding in the APEX trial
2018
-
Diamond and Forrester-predicted vs. coronary CTA-observed prevalence of obstructive CAD in patients with stable chest pain: results from the PROMISE trial
2018
-
Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL
2018
-
Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial
2018
-
Evaluation the predictive value of PARIS score for long-term out-of-hospital events after percutaneous coronary interventions
2018
-
Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE
2018
-
LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS
2018
-
Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study
2018
-
Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial
2018
-
Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial
2018
-
Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial
2018
-
Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation
2018
-
A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials
2017
-
Association between the timing of surgery for complicated infective endocarditis and survival
2017
-
Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin
2017
-
Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF)
2017
-
Diabetes and cardiovascular risk in patients with symptomatic peripheral artery disease
2017
-
Do symptoms correlate with underlying rhythm in patients after atrial fibrillation ablation?
2017
-
Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
2017
-
INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin
2017
-
Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial
2017
-
Multi-ethnic comparisons of diabetes in heart failure with reduced ejection
2017
-
Pre- and post-stroke antithrombotic therapy in atrial fibrillation patients - a Danish nation-wide registry-based study
2017
-
Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials
2017
-
Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial
2017
-
The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial
2017
-
The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID
2017
-
Ticagrelor in patients with symptomatic peripheral artery disease and prior coronary artery disease
2017
-
Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial
2017
-
A multi-time-point based multimarker risk stratification strategy in acute heart failure - results from the RELAX-AHF trial
2016
-
Comparing novel biomarkers associated with heart failure preserved ejection fraction (HFpEF): A matched case-control analysis
2016
-
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
2016
-
Mechanisms and impact on cardiac mortality of right ventricular dysfunction in non-ischaemic cardiomyopathy
2016
-
Multinational ethnic variations in self-reported health status in chronic heart failure patients
2016
-
Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation
2016
-
Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial
2016
-
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF)
2016
-
Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF)
2016
-
Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF
2016
-
Prognostic Utility of GDF-15 in Chronic Heart Failure: Insights From the HF-ACTION Study
2016
-
Sex differences in early dyspnea relief in acute heart failure
2016
-
Systemic embolization in patients with atrial fibrillation: results from ROCKET AF
2016
-
The EVEREST II REALISM Continued Access Study-1 year outcomes in patients with functional mitral regurgitation reported by baseline New York Heart Association functional class
2016
-
Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy
2015
-
Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial
2015
-
Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial
2015
-
Effect of ivabradine on heart rate variability in patients with stable coronary artery disease
2015
-
Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial
2015
-
External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation
2015
-
Hypotension in patients with acute heart failure: Insights from RELAX-AHF
2015
-
Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean following cardiothoracic surgery
2015
-
Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from a statewide quality improvement initiative in North Carolina during 2010-2013
2015
-
Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study
2015
-
Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial
2015
-
Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial
2015
-
Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results from the ROCKET AF trial
2015
-
Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings from the ROCKET AF trial
2015
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment
2015
-
Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation
2015
-
Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative
2015
-
The EVEREST II REALISM Continued Access study-1 year outcomes in patients with primary mitral regurgitation
2015
-
The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical practice?
2015
-
Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: insights from ROCKET AF
2015
-
A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score
2014
-
Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial
2014
-
Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure - insights from the platelet inhibition and patient outcomes (PLATO) trial
2014
-
Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial
2014
-
Impact of early initiation of intravenous prostanoid therapy in patients with congenital heart disease-related pulmonary arterial hypertension
2014
-
Impact of insurance status on survival in pulmonary hypertension
2014
-
Incidence and impact of patent foramen ovale among patients with pulmonary hypertension
2014
-
Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation
2014
-
Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation - Results from ROCKET AF
2014
-
Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial
2014
-
Relationship between troponin levels and long-term outcomes in medically managed patients with non-ST-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial
2014
-
The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment
2014
-
A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by
2013
-
A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in the drug-eluting stent era
2013
-
ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy
2013
-
Association between type of valve prosthesis and one year mortality in IE: an analysis of 1467 patients from the International collaboration on endocarditis prospective cohort study
2013
-
International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial
2013
-
Mechanical dyssynchrony defined by phase analysis from GSPECT: Does it predict all cause and cardiovascular mortality?
2013
-
Mode of death and factors associated with cardiac and non-cardiac death in the MADIT-RIT trial
2013
-
Reperfusion arrhythmia bursts predict larger infarct size in STEMI patients undergoing primary percutaneous coronary intervention despite optimal epicardial and microvascular flow
2013
-
Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial
2013
-
Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE
2013
-
Ventricular arrhythmia bursts following primary percutaneous coronary intervention for acute myocardial infarction: correlations with microvascular obstruction and final infarct size using CMR
2013
-
Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial
2012
-
Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis
2012
-
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia
2012
-
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial
2012
-
Hemodynamic response to hypoxia in heart failure patients with high peripheral chemosensitivity
2012
-
Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF
2012
-
Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy
2012
-
Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death
2012
-
Ischemia change in heart failure patients with stable coronary artery disease is an independent predictor of death and myocardial infarction
2012
-
NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin
2012
-
New insight into mental stress induced myocardial ischemia: prevalence and demographic/clinical characteristics
2012
-
Post-operative atrial fibrillation prophylaxis in clinical practice: results from the CAPS-Care STS registry
2012
-
Predictors of augmented peripheral chemosensitivity in patients with systolic heart failure
2012
-
Racial differences in acute aortic dissection: insights from the International Registry of Acute Aortic Dissection
2012
-
Relationship between site enrollment and outcomes in acute heart failure: insights from EVEREST trial
2012
-
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial
2012
-
Baseline hemoglobin predicts post-discharge events in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial
2012
-
Unmasked pulmonary venous hypertension during vasodilator challenge predicts poor outcomes with medical therapy
2011
-
Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality
2010
-
No significant increase in the incidence of infective endocarditis following the cessation of antibiotic prophylaxis for dental procedures
2010
-
Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION Study
2010
-
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the PREVENT-IV trial
2010
-
Troponin T not human fatty acid binding protein predicts important clinical outcomes in chronic heart failure
2008
-
A practical, validated model for prediction of risk in chronic heart failure
2006
-
Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: Insights from the CRUSADE national quality improvement initiative
2006
-
Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes
2006
-
Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention
2006
-
Racial differences in high-risk patients presenting with NSTE ACS: results from the SYNERGY trial
2006
-
Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial
2006
-
Patients with acute ST-elevation myocardial infarction and prehospital delay to presentation > 12 hours: high risk of worse outcomes and selective use of reperfusion therapies. The GRACE registry
2006
-
Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies
2005
-
Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)
2005
-
Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme
2005
-
Deriving a safety index from the GRACE risk score
2005
-
Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events
2005
-
Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
2005
-
Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme
2005
-
International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience
2005
-
Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry
2005
-
Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum
2005
-
The importance of resting wall motion abnormalities for the diagnostic accuracy of a multicomponent stress CMR test
2005
-
Use of insulin sensitizing agents in outpatients with congestive heart failure appears safe, and may have important clinical benefits when compared with sulfonylureas and insulin
2005
-
Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program
2005
-
"Leading and lagging" hospitals: can processes of care be used to rank hospitals?
2004
-
Continuous ST-segment recovery analysis is significantly more predictive of mortality than serial static analysis after thrombolytic therapy for acute MI
2004
-
Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure
2004
-
Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials
2004
-
Elevation of high density lipoprotein cholesterol and not anti-inflammatory effect accounts for the reduction in clinical events with combination gemfibrozil, niacin and cholestyramine therapy
2004
-
2704 Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus
2003
-
755 Relation of myocardial scarring to clinical risk factors for sudden death in hypertrophic cardiomyopathy
2003
-
P1022 A prospective registry of patients hospitalized for worsening heart failure: observations from the IMPACT-HF registry
2003
-
P1102 Mechanism of pexelizumabs mortality benefit in acute myocardial infarction patients treated with primary percutaneous coronary intervention
2003
-
P1627 Does infarct size measured by creatine kinase-MB predict clinical outcomes after fibrinolysis and primary percutaneous coronary intervention?
2003
-
P2848 Enoxaparin versus unfractionated heparin with tenecteplase in the elderly: combined ASSENT-3 and ASSENT-3 PLUS results
2003
-
P2856 Cumulative meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
2003
-
P2865 Treating patients with acute coronary syndromes with aggressive anti-platelet agents in the grace registry: no observed decrease in in-hospital mortality but increased bleeding complications
2003
-
P2870 Elective percutaneous coronary intervention using anti-platelet therapy alone, without unfractionated heparin or other anti-thrombin therapy
2003
-
Cost-effectiveness of valsartan in patients not receiving angiotensin-converting enzyme inhibitors at baseline
2002
-
Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction
2002
-
How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3
2002
-
Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE)
2002
-
TNK with reduced dose unfractionated heparin associated with similar efficacy and less bleeding: results from ASSENT-2 and ASSENT-3
2002
-
Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure
2001
-
Perspectives gained from large-scale thrombolytic comparative trials.
1996
-
Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers.
1995
-
Regional left ventricular diastolic properties during pacing induced ischemia in dogs with coronary stenoses
1981